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The Paediatric Regulation (1) was launched ten years ago. As was
also identified in the ten year report (2), this regulation has had a
positive impact on paediatric research in Europe. However, some
specific patient populations (such as neonates, critically ill children,
children with comorbidities) do not receive enough attention in
paediatric drug development. Furthermore, the top-down
approach (from adults to children) results in considerable delays in
making medicines available to children. For most of the drugs long
term follow-up is missing.
The SAFE-PEDRUG project was initiated in Belgium in 2014 and is a
collaboration of experts in paediatrics, pharmaceutical sciences,
veterinary medicine, and ethics of three Belgian universities: Ghent
University, KULeuven, and Vrije Universiteit Brussel. An advisory
board and stakeholder group consisting of national and
international stakeholders support this consortium in the
valorisation of results.
The SAFE-PEDRUG project explored the value of the porcine
juvenile animal model and modelling and simulation (population
pharmacokinetics and physiologically based pharmacokinetic
modelling) in providing prior paediatric PK/PD knowledge, before
the actual adult trials have been completed. For the evaluation of
this approach, three case compounds were selected: desmopressin,
lisinopril, and fluoroquinolones. The results of the models are
plotted against human paediatric data, including data in neonates
and critically ill children.
A close collaboration of experts and stakeholders can help to tailor
paediatric clinical trials to the needs of children. Pharmaceutical
industry and regulatory authorities are key players in the paediatric
drug development process. However, academia can also play an
important role in rendering the paediatric drug development
process more efficient by development and correct use of
innovative tools (figure 1). Besides, academia should defend the
rights of the most important stakeholders: patients and their
parents. During the SAFE-PEDRUG project additional opportunities
for academia have been identified: initiation of networking;
centralisation in registries and networks to improve transparency
and efficiency; and education of paediatric clinical pharmacologists.
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Figure 1: Timelines for paediatric drug research. Opportunities for
paediatric drug research (indicated in yellow).
MA: marketing authorisation
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